{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:33:35Z","timestamp":1786980815905,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07759-1","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:47:22Z","timestamp":1755848842000},"page":"943-951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3579-9141","authenticated-orcid":false,"given":"Muzamil","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheema","family":"Saadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish Ali","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmood","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ali","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"7759_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1160\/TH07-03-0212","volume":"98","author":"A Cohen","year":"2007","unstructured":"Cohen A, Agnelli G, Anderson F, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost. 2007;98:756\u201364. https:\/\/doi.org\/10.1160\/TH07-03-0212.","journal-title":"Thromb Haemost"},{"key":"7759_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5133","volume":"347","author":"LA Castellucci","year":"2013","unstructured":"Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347: f5133\u2013f5133. https:\/\/doi.org\/10.1136\/bmj.f5133.","journal-title":"BMJ"},{"key":"7759_CR3","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.amjcard.2018.06.035","volume":"122","author":"V Bhalla","year":"2018","unstructured":"Bhalla V, Abdel-Latif A, Bhalla M, et al. Meta-analysis comparing the efficacy, safety, and cost-benefit of direct acting oral anticoagulants versus enoxaparin thromboprophylaxis to prevent venous thromboembolism among hospitalized patients. Am J Cardiol. 2018;122:1236\u201343. https:\/\/doi.org\/10.1016\/j.amjcard.2018.06.035.","journal-title":"Am J Cardiol"},{"key":"7759_CR4","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"7759_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928\u2013d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"7759_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1700518.","journal-title":"N Engl J Med"},{"key":"7759_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1207541.","journal-title":"N Engl J Med"},{"key":"7759_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416112","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2416112.","journal-title":"N Engl J Med"},{"key":"7759_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","volume":"405","author":"F Couturaud","year":"2025","unstructured":"Couturaud F, Schmidt J, Sanchez O, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405:725\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(24)02842-3.","journal-title":"Lancet"},{"key":"7759_CR10","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/jth.14156","volume":"16","author":"L Vasanthamohan","year":"2018","unstructured":"Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018;16:1288\u201395. https:\/\/doi.org\/10.1111\/jth.14156.","journal-title":"J Thromb Haemost"},{"key":"7759_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","volume":"392","author":"PM Rothwell","year":"2018","unstructured":"Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387\u201399. https:\/\/doi.org\/10.1016\/S0140-6736(18)31133-4.","journal-title":"Lancet"},{"key":"7759_CR12","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1111\/bcp.13968","volume":"85","author":"SB Dimmitt","year":"2019","unstructured":"Dimmitt SB, Floyd CN, Ferner RE. Antithrombotic dose: some observations from published clinical trials. Br J Clin Pharmacol. 2019;85:2194\u20137. https:\/\/doi.org\/10.1111\/bcp.13968.","journal-title":"Br J Clin Pharmacol"},{"key":"7759_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/jth.15776","volume":"20","author":"PL den Exter","year":"2022","unstructured":"den Exter PL, Woller SC, Robert-Ebadi H, et al. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC subcommittee on predictive and diagnostic variables in thrombotic disease. J Thromb Haemost. 2022;20:1910\u20139. https:\/\/doi.org\/10.1111\/jth.15776.","journal-title":"J Thromb Haemost"},{"key":"7759_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1182\/asheducation-2018.1.432","volume":"2018","author":"W Ageno","year":"2018","unstructured":"Ageno W, Donadini M. Breadth of complications of long-term oral anticoagulant care. Hematology. 2018;2018:432\u20138. https:\/\/doi.org\/10.1182\/asheducation-2018.1.432.","journal-title":"Hematology"},{"key":"7759_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/EBP.0000000000001136","volume":"24","author":"M Schneider","year":"2021","unstructured":"Schneider M, Kim I. Apixaban better than rivaroxaban? Evidence-Based Practice. 2021;24:7\u20137. https:\/\/doi.org\/10.1097\/EBP.0000000000001136.","journal-title":"Evidence-Based Practice"},{"key":"7759_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.hrthm.2024.08.033","volume":"22","author":"M Shurrab","year":"2025","unstructured":"Shurrab M, Austin PC, Jackevicius CA, et al. Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: a population-based cohort study. Heart Rhythm. 2025;22:961\u201370. https:\/\/doi.org\/10.1016\/j.hrthm.2024.08.033.","journal-title":"Heart Rhythm"},{"key":"7759_CR17","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1182\/blood-2022-157703","volume":"140","author":"D Fredman","year":"2022","unstructured":"Fredman D, McNeil R, Eldar O, et al. Efficacy and safety of rivaroxaban versus apixaban in patients with venous thromboembolism: a systematic review and meta-analysis of observational studies. Blood. 2022;140:5664\u20135. https:\/\/doi.org\/10.1182\/blood-2022-157703.","journal-title":"Blood"},{"key":"7759_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/ajh.26996","volume":"98","author":"K Giorgio","year":"2023","unstructured":"Giorgio K, Walker RF, MacLehose RF, et al. Venous thromboembolism mortality and trends in older US adults, 2011\u20132019. Am J Hematol. 2023;98:1364\u201373. https:\/\/doi.org\/10.1002\/ajh.26996.","journal-title":"Am J Hematol"},{"key":"7759_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2020.09.007","volume":"83","author":"R Cappato","year":"2021","unstructured":"Cappato R, Chiarito M, Giustozzi M, et al. Lower dose direct oral anticoagulants and improved survival: a combined analysis in patients with established atherosclerosis. Eur J Intern Med. 2021;83:14\u201320. https:\/\/doi.org\/10.1016\/j.ejim.2020.09.007.","journal-title":"Eur J Intern Med"},{"key":"7759_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jacc.2021.01.024","volume":"77","author":"JL Halperin","year":"2021","unstructured":"Halperin JL, Rashed ER. Low-dose anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2021;77:1208\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.024.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07759-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:48Z","timestamp":1778649708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07759-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7759"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07759-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"4 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}